RPL35AP26: A Promising Drug Target / Biomarker (G100271630)

Target Name: RPL35AP26

NCBI ID: G100271630

RPL35AP26

Other Name(s): Ribosomal protein L35a pseudogene 26 | ribosomal protein L35a pseudogene 26 | RPL35A_11_1187

RPL35AP26: A Promising Drug Target / Biomarker

The RPL35AP26 gene is located on chromosome 6p21.2 and has been identified as a potential drug target or biomarker for various psychiatric and neurological disorders. The RPL35AP26 gene encodes a protein that is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Synaptic plasticity is a critical factor in the development and progression of many psychiatric and neurological disorders, including depression, anxiety, and schizophrenia. The RPL35AP26 gene has been shown to play a role in the regulation of synaptic plasticity, which may have implications for the development of these disorders.

Drug Target Potential

The RPL35AP26 gene has been identified as a potential drug target for the treatment of psychiatric and neurological disorders. The RPL35AP26 protein has been shown to play a role in the regulation of synaptic plasticity, which may be a potential target for the development of these disorders.

One of the potential benefits of targeting the RPL35AP26 gene is that it has been shown to have therapeutic effects on symptoms of psychiatric and neurological disorders. For example, studies have shown that the RPL35AP26 gene has been associated with the development of symptoms of depression, anxiety, and schizophrenia. By targeting this gene, researchers may be able to develop new treatments for these disorders.

Biomarker Potential

In addition to its potential as a drug target, the RPL35AP26 gene may also be a useful biomarker for the diagnosis and progression of psychiatric and neurological disorders. The RPL35AP26 protein has been shown to be expressed in the brains of individuals with depression, anxiety, and schizophrenia, which may suggest that it could be a useful biomarker for these disorders.

The RPL35AP26 gene has also been shown to be involved in the regulation of synaptic plasticity, which is a critical factor in the development and progression of many psychiatric and neurological disorders. By targeting this gene, researchers may be able to develop new treatments for these disorders and improve our understanding of their underlying causes.

Conclusion

In conclusion, the RPL35AP26 gene has been identified as a potential drug target and biomarker for various psychiatric and neurological disorders. The RPL35AP26 protein has been shown to play a role in the regulation of synaptic plasticity, which may have implications for the development of these disorders. Further research is needed to fully understand the role of the RPL35AP26 gene in the regulation of synaptic plasticity and the potential of targeting this gene as a drug target or biomarker for the treatment of psychiatric and neurological disorders.

Protein Name: Ribosomal Protein L35a Pseudogene 26

The "RPL35AP26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL35AP26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets